

**IN THE UNITED STATES DISTRICT COURT  
DISTRICT OF MASSACHUSETTS**

**SANOFI-AVENTIS U.S. LLC; GENZYME  
CORPORATION; AND REGENERON  
PHARMACEUTICALS, INC.,**

**Plaintiffs,**

**v.**

**AMGEN INC. AND IMMUNEX  
CORPORATION,**

**Defendants.**

**Civil Action No. 1:17-cv-10465-NMG**

**PLAINTIFFS' NOTICE OF  
VOLUNTARY DISMISSAL  
PURSUANT TO  
FED. R. CIV. P. 41(a)(1)(A)(i)**

**PLAINTIFFS' NOTICE OF  
VOLUNTARY DISMISSAL PURSUANT TO FED. R. CIV. P. 41(a)(1)(A)(i)**

Pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i), Plaintiffs Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc., by and through their undersigned attorneys, hereby give notice that the above-captioned action is voluntary dismissed, without prejudice, against Defendants Amgen Inc. and Immunex Corporation.

Dated: May 1, 2017

Respectfully submitted,

/s/ John F. Garvish

David L. Evans (BBO No. 156695)  
devans@murphyking.com  
Theodore J. Folkman (BBO No. 647642)  
tfolkman@murphyking.com  
Amanda Rettig (BBO No. 653900)  
arettig@murphyking.com  
MURPHY & KING, P.C.  
One Beacon St.  
Boston, Mass. 02108  
Telephone: (617) 423-0400  
Facsimile: (617) 423- 0498

Mike McKool, Jr. (*pro hac vice*)  
mmckool@mckoolsmith.com  
McKOOL SMITH, P.C.  
300 Crescent Court, Suite 1500  
Dallas, Texas 75201  
Telephone: (214) 978-4000  
Facsimile: (214) 978-4044

John F. Garvish (*pro hac vice*)  
jgarvish@mckoolsmith.com  
Geoffrey L. Smith (*pro hac vice*)  
gsmith@mckoolsmith.com  
Christine M. Woodin (*pro hac vice*)  
cwoodin@mckoolsmith.com  
Matthew T. Cameron (*pro hac vice*)  
McKOOL SMITH, P.C.  
300 W. 6th St., Ste. 1700  
Austin, Texas 78701  
Telephone: (512) 692-8700  
Facsimile: (512) 692-8744

Radu A. Lelutiu (*pro hac vice*)  
rlelutiu@mckoolsmith.com  
Lauren L. Fornarotto (*pro hac vice*)  
lfornarotto@mckoolsmith.com  
McKOOL SMITH, P.C.  
One Bryant Park, 47th Floor  
New York, NY 10036  
Telephone: (212) 402-9400  
Facsimile: (212) 402-9444

*ATTORNEYS FOR PLAINTIFFS*  
*SANOFI-AVENTIS U.S. LLC; GENZYME CORPORATION; AND*  
*REGENERON PHARMACEUTICALS, INC.*

**CERTIFICATE OF SERVICE**

I hereby certify that this document filed through the ECF system will be sent electronically to the registered participants, as identified on the Notice of Electronic File (“NEF”), and paper copies will be sent to those indicated as non-registered participants on May 1, 2017 by first class mail.

*/s/ John F. Garvish*

\_\_\_\_\_  
John F. Garvish